Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

NCT02273661 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

174

Enrollment

OTHER

Sponsor class

Conditions

Allergic Bronchopulmonary Aspergillosis

Interventions

DRUG: Liposomal amphotericin B (Ambisome®)
DRUG: placebo

Sponsor

Poitiers University Hospital